PhytoHealth

「PG2 Lyo. Injection 500mg 」

Received “Orphan Drug Designation” status for treating Idiopathic thrombocytopenic purpura ( ITP) from FDA.

Extends its medical indication to treat stroke patients and be implemented the clinical trials by the stroke specialist in medical
center continually.

「PHN031」&「PHN033」

「PHN031」&「PHN033」were chosen to be the Cross-Strait Drug
Co-Development Projects. The CFDA’s Guidelines-compliant CMC(Chemistry, Manufacturing and Control )are underprepared.

「PHN031」

has completed US FDA Phase IIa clinical trials for the prevention of osteoporosis.

「PHN033」

has completed US FDA Phase IIa clinical trials for the treatment of diabetic nephropathy.

「PHN131」

「PHN131」for pain relief, has completed the pivotal clinical trials and statistical report . Submit to TFDA to apply New Drug Application on 2016.